Combination Cancer Therapy (Record no. 244156)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 03656nam a22004695i 4500 |
001 - CONTROL NUMBER | |
control field | 978-1-59259-864-9 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20160614135125.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 100301s2005 xxu| s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9781592598649 |
-- | 978-1-59259-864-9 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1385/1592598641 |
Source of number or code | doi |
049 ## - LOCAL HOLDINGS (OCLC) | |
Holding library | Alfaisal Main Library |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RC254-282 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MJCL |
Source | bicssc |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MED062000 |
Source | bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 616.994 |
Edition number | 23 |
245 10 - TITLE STATEMENT | |
Title | Combination Cancer Therapy |
Medium | [electronic resource] : |
Remainder of title | Modulators and Potentiators / |
Statement of responsibility, etc | edited by Gary K. Schwartz. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE STATEMENTS | |
Place of production, publication, distribution, manufacture | Totowa, NJ : |
Name of producer, publisher, distributor, manufacturer | Humana Press, |
Date of production, publication, distribution, manufacture | 2005. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | X, 284 p. |
Other physical details | online resource. |
336 ## - CONTENT TYPE | |
Content Type Term | text |
Content Type Code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media Type Term | computer |
Media Type Code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier Type Term | online resource |
Carrier Type Code | cr |
Source | rdacarrier |
347 ## - | |
-- | text file |
-- | |
-- | rda |
490 1# - SERIES STATEMENT | |
Series statement | Cancer Drug Discovery and Development |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Targeting of the EGFR As a Modulator of Cancer Chemotherapy -- Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy -- Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia -- Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry -- Targeted ?-Particle Therapy -- Pharmacological Modulation of Fluoropyrimidines -- Development of Inhibitors of HER2 With Taxanes -- Targeting NF-?B to Increase the Activity of Cisplatin in Solid Tumors -- Combinations of Chemotherapy and G3139, an Antisense Bcl-2 Oligonucleotide -- Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy. |
520 ## - SUMMARY, ETC. | |
Summary, etc | Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics. Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Medicine. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Oncology. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Medicine & Public Health. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Oncology. |
655 #7 - INDEX TERM--GENRE/FORM | |
Genre/form data or focus term | Electronic books. |
Source of term | local |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Schwartz, Gary K. |
Relator term | editor. |
710 2# - ADDED ENTRY--CORPORATE NAME | |
Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY | |
Title | Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Display text | Printed edition: |
International Standard Book Number | 9781588292001 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Cancer Drug Discovery and Development |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1385/1592598641">http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1385/1592598641</a> |
912 ## - | |
-- | ZDB-2-SME |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Source of classification or shelving scheme | Library of Congress Classification |
Koha item type | eBooks |
No items available.